Curium Pharma

Curium Pharma, founded in 2017 and headquartered in Paris, France, is a commercial-stage company and self-proclaimed global leader in nuclear medicine. It operates a fully integrated business model encompassing development, manufacturing, and global supply of a broad portfolio of over 50 diagnostic and therapeutic radiopharmaceuticals. With significant infrastructure including four manufacturing sites, 44 radiopharmacies, and a molybdenum processing plant, Curium serves over 6,000 customers in more than 60 countries. The company is executing a 2030 vision to solidify its position as an oncology-focused leader, expanding into key Asian markets and investing in new technologies, including artificial intelligence for image analysis.

Integrated radiopharmaceutical platform for diagnostics (e.g., SPECT imaging agents) and targeted radioligand therapy. Investing in AI for image analysis and diagnostic support.

The radiopharmaceutical market is becoming increasingly competitive, with major players like Novartis (with Pluvicto and Lutathera) making large investments. Curium competes on its broad diagnostic portfolio, integrated supply chain, and global commercial reach, but must innovate in therapeutics to maintain leadership.